| Identification | Back Directory | [Name]
Metroprolol succinate | [CAS]
98418-47-4 | [Synonyms]
rolol succinate
METOPROLOL SUCCINATE
metroprolol succinate
Metoprolol Succinate (200 mg)
Metoprolol Succinate (ToprolX)
Metoprolol Succinate (200 mg)F0C4150.998mg/mg(ai)
2-Propanol, 1-(4-(2-Methoxyethyl)phenoxy)-3-((1-Methylethyl)aMino)-, (+-)-, butanedioate (2:1) (salt) | [EINECS(EC#)]
620-476-9 | [Molecular Formula]
2C15H25NO3.C4H6O4 | [MDL Number]
MFCD07391179 | [MOL File]
98418-47-4.mol | [Molecular Weight]
652.82 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
136-138°C | [storage temp. ]
Hygroscopic, Refrigerator, under inert atmosphere | [solubility ]
Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent), very slightly soluble in ethyl acetate. | [form ]
neat | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChI]
InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8) | [InChIKey]
RGHAZVBIOOEVQX-UHFFFAOYSA-N | [SMILES]
C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1 |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Definition]
ChEBI: Metoprolol succinate is an alcohol and a member of phenols. | [Brand name]
Toprol (AstraZeneca). | [in vivo]
Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) reduces proinflammatory cytokines and atherosclerosis in ApoE?/? Mice[1].
Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis[2].
Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats[4]. | Animal Model: | Male ApoE?/? mice[1] | | Dosage: | 2.5?mg/kg/h | | Administration: | Via osmotic minipumps, 11 weeks | | Result: | Significantly reduced atherosclerotic plaque area in thoracic aorta, reduced serum TNFα and the chemokine CXCL1 as well as decreasing the macrophage content in the plaques. |
| Animal Model: | Balb/c mice, coxsackievirus B3 (CVB3) induced viral myocarditis (VMC) model[2] | | Dosage: | 15 mg/kg/q12h
| | Administration: | Oral gavage, 5 consecutive days | | Result: | Reduced pathological scores of VMC induced by CVB3 infection, protected the myocardium against viral damage by reducing serum cTn-I levels. Decreased the levels of myocardial pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokine. Significantly decreased myocardial virus titers. |
| [IC 50]
β1 adrenoceptor | [storage]
Store at -20°C |
|
|